Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly be watching closely for financial updates, forward guidance, and surprises that could move the market. To dive deeper into any of the companies listed below, click on their ticker symbols, as TipRanks‘ unique datasets will help you research the stocks and decide whether they are a Buy, Sell, or Hold.

Meet Samuel – Your Personal Investing Prophet

High conviction NVDA bears now have this Tradr ETF

A.M. Earnings – TGT -4.36% ▼ , LOW -0.36% ▼ , ZIM -1.45% ▼ , TJX +6.04% ▲ , ADI -7.07% ▼ , (VF), HAS -8.15% ▼

P.M. Earnings – NVDA +2.03% ▲ , INTU -3.34% ▼ , ELF -2.45% ▼ , URBN +2.61% ▲

For the full list, visit TipRanks’ earnings calendar.

Disclaimer & DisclosureReport an Issue

The Vanguard Total Stock Market ETF VTI +0.95% ▲ , which tracks the broader U.S. stock market, rose about 0.47% at the market open on Wednesday. The move came as chip stocks stabilized ahead of Nvidia’s NVDA +2.00% ▲ earnings, which investors see as a key test of AI demand.

Meet Samuel – Your Personal Investing Prophet

Explore AMZO for 2X short leverage on AMZN

Overall, the VTI ETF remains up by 8.42% year-to-date. Meanwhile, its three-month average trading volume stands at around 4.83 million shares.

VTI’s Top Holdings

Currently, VTI holds 3,473 stocks with total assets worth $641.46 billion. Its top positions are:

• Nvidia – 6.39%
• Apple AAPL +0.02% ▲ – 5.91%
• Microsoft MSFT -0.17% ▼ – 4.36%
• Amazon AMZN +1.97% ▲ – 3.19%
• Alphabet GOOGL -0.88% ▼ – 2.66%

VTI’s Price Forecast

According to TipRanks’ unique ETF analyst consensus, determined based on a weighted average of analyst ratings on its holdings, VTI is a Moderate Buy. The Street’s average price target of $432.54 implies an upside of 19.71%. 

Currently, VTI’s three holdings with the highest upside potential are:

1. Claros Mortgage Trust CMTG +5.21% ▲
2. Sangamo Therapeutics SGMO -7.01% ▼
3. Reviva Pharmaceuticals Holdings RVPH +0.89% ▲

Notably, VTI ETF’s Smart Score is seven, implying that this ETF is likely to perform in line with the broader market.

Disclaimer & DisclosureReport an Issue

Vanguard S&P 500 ETF VOO +0.83% ▲ and Vanguard Total Stock Market ETF VTI +0.95% ▲ are two of the most popular ETFs for long-term investors in the U.S. stock market. VOO tracks the S&P 500, giving investors exposure to 500 of the largest U.S. companies, while VTI is broader, covering nearly the entire U.S. stock market. Using TipRanks’ ETF Comparison Tool, we compare both ETFs to identify which Vanguard fund may be better positioned for investors in 2026.

Meet Samuel – Your Personal Investing Prophet

200% short exposure to AMZN with AMZO

In terms of risk, both VOO and VTI move closely with the broader U.S. market. VOO has a beta of 0.99, while VTI is slightly higher at 1.01, meaning VTI is just a bit more sensitive to market swings. This difference mainly comes from VTI’s exposure to mid- and small-cap stocks, which tend to be more volatile than large-cap companies.

Let’s break it down.

Vanguard S&P 500 ETF VOO +0.83% ▲

The Vanguard S&P 500 ETF (VOO) is a popular choice for investors looking for direct exposure to large U.S. companies. It tracks the S&P 500 Index (SPX), which is widely viewed as a key benchmark for the overall U.S. stock market and a reflection of the broader economy.

In terms of holdings, VOO is heavily tilted toward the technology sector and currently holds 507 stocks with total assets of about $961.23 billion. However, it is more concentrated at the top compared to VTI. Its top 10 holdings account for 38.35% of total assets, versus 32% for VTI, meaning a larger share of performance is driven by a few mega-cap companies.

VOO’s largest positions include Nvidia NVDA +2.00% ▲ , Apple AAPL +0.02% ▲ , Microsoft MSFT -0.17% ▼ , Amazon AMZN +1.97% ▲ , and Alphabet GOOGL -0.88% ▼ .

Is VOO ETF a Good Buy?

According to TipRanks’ unique ETF analyst consensus, determined based on a weighted average of analyst ratings on its holdings, VOO is a Moderate Buy. The Street’s average price target of $801.11 implies an upside of 18.60%.

Vanguard Total Stock Market ETF VTI +0.95% ▲

The Vanguard Total Stock Market ETF (VTI) offers investors exposure to nearly the entire U.S. stock market, holding thousands of companies across large-, mid-, and small-cap segments. This makes it a simple, highly diversified core option for long-term investors who want broad market coverage in a single fund.

Like VOO, VTI is still weighted toward mega-cap stocks because the largest companies dominate the market today. However, VTI is slightly more diversified overall. It currently holds 3,473 stocks and manages about $641.46 billion in total assets.

VTI’s top holdings—Nvidia, Apple, Microsoft, Amazon, and Alphabet—are the same as VOO’s. The key difference is not the top stocks, but the broader exposure VTI provides beyond the largest companies, giving investors access to a wider slice of the U.S. economy.

Is VTI ETF a Good Buy?

According to TipRanks’ unique ETF analyst consensus, determined based on a weighted average of analyst ratings on its holdings, VTI is a Moderate Buy. The Street’s average price target of $432.54 implies an upside of 20%. 

Conclusion

Both VOO and VTI are strong, low-cost ETFs for long-term investing. VTI may have a small advantage for long-term wealth building because it includes small- and mid-cap companies, which add more diversification and have often shown stronger growth over time.

VOO is simpler and more focused. It tracks only large U.S. companies, which can make it feel more stable and easier to understand for many investors.

Disclaimer & DisclosureReport an Issue

Bristol Myers Squibb BMY +0.20% ▲ , a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its Claude AI model to more than 30,000 staff members.

Meet Samuel – Your Personal Investing Prophet

NVDS: built for a short position on NVDA

The goal is clear: Bristol Myers wants to use AI to help speed up how it finds, tests, makes, and sells new drugs. The company also said it will use Claude Code, Anthropic’s coding tool, and test it across research, drug development, manufacturing, medical affairs, and sales work.

In short, this is not just about giving staff a chatbot. Bristol Myers wants Claude to help teams work with large pools of data that have long been hard to use. Greg Meyers, the company’s chief digital and technology officer, said, “Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos.”

Meanwhile, BMY shares rose 1.74% on Tuesday, closing at $58.31.

Pharma Keeps Betting on AI

Meanwhile, Bristol Myers is not alone. Drug firms are racing to see how AI can cut time, lower costs, and raise the odds that new drugs make it through trials. Eli Lilly LLY -1.26% ▼ , for example, has worked with Nvidia NVDA +2.00% ▲ as part of its own AI push.

For investors, the key point is that this deal is a long-term play. It may not change Bristol Myers’ sales right away. However, if AI helps the company move faster in drug research and clinical work, it could support margins and growth over time.

That said, AI is still a tool, not a cure-all. Bristol Myers will need to show that Claude can do more than boost office speed. The real test will be whether it helps the company bring better drugs to market with less waste and more focus.

Is BMY a Good Stock to Buy Now?

Turning to the Street, Bristol Myers has a Moderate Buy consensus, based on 14 analysts’ ratings. The average MBY stock price target is $63.18, implying an 8.36% upside from the current price.

Disclaimer & DisclosureReport an Issue